Genfit’s Post-NASH Plans Center On ACLF, Cholestatic Liver Disease

After last year’s Phase III failure in NASH, Genfit sees big opportunity in acute on chronic liver failure (ACLF), potentially with antiviral NTX. Its ongoing Phase III program in PBC as also is a potential revenue-driver.

Brainstorming Group of people Working Concept. Business team brainstorming. Marketing plan researching. Paperwork on the table, laptop and mobile phone.
Genfit is moving on from NASH, into rare liver indications

One year after its Phase III failure in non-alcoholic steatohepatitis (NASH) with elafibranor, Genfit SA outlined its new R&D focus for investors on 11 May, headlined by a strategy to test a now-generic anti-infective drug in acute on chronic liver failure (ACLF). The French firm’s focus also remains on a pivotal Phase III study of elafibranor in second-line primary biliary cholangitis (PBC), as well as plans to test the drug and a second internally discovered PPAR agonist in first-line PBC as well as primary sclerosing cholangitis (PSC).

More from Strategy

Oculis Eyes Opportunities For Third Ophthalmology Candidate

 
• By 

The Swiss-headquartered, NASDAQ-listed group has posted a Phase II win for OCS-05 in acute optic neuritis, which opens up its potential in additional, and much larger, neuro-ophthalmic indications, CEO Riad Sherif tells Scrip.

Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular

 

Plus deals involving Pfizer/Atavistik, Immedica/Marinus, J&J/Kaken, Ikena/Inmagene, Corxel/Vincentage, Rapt/Jemincare, Sanofi/Corxel, Bristol Myers Squibb/BioArctic, NGM/kdT Ventures and more.

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By 

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

New Year’s Hangover: Neumora’s Phase III Failure In Depression Surprises

 
• By 

Neumora, one of two firms testing kappa opioid receptor antagonism in depression, failed its first of three Phase III studies. The company’s share price crashed sharply.

More from Business